Energizer highlights partnership with iAd
ST. LOUIS — Energizer has rolled out a new mobile marketing campaign on Apple’s iAd network to emphasize its partnership with the VH1 Save The Music Foundation.
The "Unleash Your Inner Rock Star" iAd, which was developed by TBWA\Chiat\Day Los Angeles, underscores its partnership with the organization — whereby Energizer is helping restore instrumental music education in public schools with a $250,000 donation and grants of donated instruments to eight schools in need — by allowing users to interact with Energizer by utilizing the accelerometer on the iPhone and iPod Touch. Consumers can recreate such rock star moves as the windmill on guitar and hit the cymbals on a drum set.
"The iAd lets mobile phone users experience the Energizer brand in a new way," Energizer North America marketing communications manager Serge Traylor said. "By focusing on mobile we can provide entertainment and information to people anywhere, not just when they are seated at their computer, and we’re excited to let our unstoppable icon interact with consumers in new and different ways to deliver this information."
Click here to view a demonstration of the iAd.
Stater Bros. appoints SVP retail operations
SAN BERNARDINO, Calif. — Stater Bros. has promoted its senior regional VP.
The Southern California-based supermarket chain said that Dan Meyer, a 41-year company veteran, has been promoted to the newly created role of SVP retail operations. In this capacity, Meyer will be responsible for the retail operations of all 167 Stater Bros. stores, as well as overseeing the day-to-day operations of the Corporate Training Center. Meyer will report to George Frahm, EVP retail operations and administration.
"Dan is a well-respected and valuable member of our senior management team," Stater Bros. board chairman and CEO Jack Brown said. "This promotion is a result of his leadership skills and the contributions that he has made towards the success of the company’s retail operations department."
Orexigen, FDA work out plan for path to approval of obesity drug
SAN DIEGO — Drug maker Orexigen Therapeutics said it had identified a "clear and feasible path" for the approval of its drug for treating obesity by working with the Food and Drug Administration.
The drug maker said this week that after meeting with officials from the FDA’s Office of New Drugs, it received a list of requirements from the agency about how to design a trial for Contrave (naltrexone and bupropion hydrochloride). The FDA, which declined to approve the drug in January, required that the trial be based on an intent-to-treat analysis, as well as criteria for interpreting the results at interim and final analyses that are similar to those applied to diabetes drugs.
"We have been working with clinical experts, advocacy groups and our partner, Takeda, throughout this process and are pleased with the feedback provided by FDA that identified a very clear and feasible path forward for this important therapy," Orexigen president and CEO Michael Narachi said.